07 September 2021 : Original article
Sofosbuvir/Velpatasvir Prophylaxis for 12 Weeks in Hepatitis C Virus (HCV)-Negative Recipients Receiving Kidney Transplantation from HCV-Positive Donors
Ruoyang Chen1BCEF, Dawei Li1BCDFG, Ming Zhang1AC, Xiaodong Yuan1ADEF*DOI: 10.12659/AOT.933313
Ann Transplant 2021; 26:e933313
Table 1 Demographic and clinical characteristics of recipient and donor.
| Recipient characteristics (n=26) | |
|---|---|
| Median age (IQR), years | 42 (20~73) |
| Male, n (%) | 19 (73.1%) |
| Median body mass index, kg/m | 23.295 (17.03~33.66) |
| Cirrhosis, n (%) | 0 |
| ALT level (U/L) | 10.5 (3~70) |
| Serum creatinine level (μmol/L) | 894 (373~1705) |
| eGFR (mL/min) | 7.715 (4~20.77) |
| Primary cause of renal failure (n=26) | |
| IgA nephropathy | 4 |
| PKD | 3 |
| FSGS | 3 |
| DN | 0 |
| HN | 1 |
| Unknown cause | 15 |
| History of diabetes (n) | 2 |
| HBsAg-positive (n) | 2 |
| HCV Ab-positive (n) | 0 |
| Median time on dialysis before transplantation (d) | 330 (0~4340) |
| Median time on waitlist before transplantation (d) | 198 (29~865) |
| Induction immunosuppression, (n=26) | |
| rATG+prednisone | 23 |
| Basiliximab+prednisone | 2 |
| Prednisone | 1 |
| Maintenance immunosuppression, (n=26) | |
| FK+MPA+Pred | 26 |
| Male, n (%) | 14 (93.3%) |
| Cause of death, (n) | |
| DBD | 13 |
| DCD | 2 |
| Median terminal serum creatine (μmol/L) | 84.5 (24~194.5) |
| ALT – alanine aminotransferase; eGFR – estimated glomerular filtration rate; PKD – polycystic kidney disease; FSGS – focal segmental glomerulosclerosis; DN – diabetic nephropathy; HN – hypertensive nephrosclerosis; rATG – rabbit anti-human thymocyte; FK – tacrolimus; MPA – mycophenolic acid; DBD – donation after brain death; DCD – donation after cardiac death. | |